Nature, Published online: 27 October 2026; doi:10.1038/d41586-026-03390-8 Regulatory pushback stalled the field. But researchers are optimistic about mind-altering drugs as potential treatments for depression and mood disorders.
Why pharma firms are betting billions on psychedelic drugs despite setbacks
In short
However, researchers are cautiously optimistic about the potential of these substances as treatments for depression and mood disorders. Despite setbacks, pharma firms are now betting billions on the future of psychedelic drugs, driven by the promise of new treatments for mental health conditions.
Key points
- However, researchers are cautiously optimistic about the potential of these substances as…: However, researchers are cautiously optimistic about the potential of these substances as treatments for depression and mood disorders.
- Despite setbacks, pharma firms are now betting billions on the future of psychedelic drug…: Despite setbacks, pharma firms are now betting billions on the future of psychedelic drugs, driven by the promise of new treatments for mental health conditions.